Biogen Swings to Q3 2026 Net Loss of $20.6 Million
Bitget2026/10/28 10:01- Biogen swung to a third-quarter 2026 GAAP diluted loss of $0.14 per share, primarily due to transaction-related charges.
- Total revenue rose 11% year over year to $2.8 billion.
- Rare disease revenue climbed 27% to $676.3 million, while multiple sclerosis revenue fell 13% to $919.3 million year over year.
- Top-line results from both Phase 3 litifilimab studies in systemic lupus erythematosus are expected in the first half of December 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
